Recent Updates
Recently added Catalysts
VYGR

Voyager Therapeutics to Participate in September Investor Conferences

Key Takeaway: CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases today announced its participation at the upcoming investor conferences: 2017 W

Full Press Release Details

CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases today announced its participation at the upcoming investor conferences:
2017 Wells Fargo Healthcare Conference, Boston, MA
Date: September 6, 2017
Presenter:  Bernard Ravina, M.D., M.S., chief medical officer
Morgan Stanley Global Healthcare Conference, New York City
Date: September 11, 2017
Presenters:  Steven Paul, M.D., chief executive officer, Jane Henderson, chief financial officer
Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com.  The webcast will be archived for 30 days after the live event concludes.
Members of Voyager’s management team will also attend the following investor conferences for one-on-one meetings:
Citi Annual Biotechnology Conference, Boston, MA
Date: September 7, 2017
Mizuho Biotechnology Conference 2017: CNS, Boston, MA
Date: September 19, 2017
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases.  Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques.  The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.  Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.  Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts.  For more information, please visit www.voyagertherapeutics.com.  Follow Voyager on LinkedIn.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: Aug 30, 2017